Projects Sponsored by the CLL Foundation

Home

Donating

What is CLL

Projects

Information

Other Sites

Board of Directors

Memorial

          RESEARCH STUDIES:

• A Genetic Approach to the Adoptive T Cell Therapy for CLL.  Lead investigator:  Renier J. Brentjens, M.D., Memorial Sloan-Kettering Cancer Center.  Dr. Brentjen's study was funded as a memorial to the late William D. Hoops, founder and first president of the Chronic Lymphocytic Leukemia Foundation.
• A Genetic Approach to the Adoptive T Cell Therapy for CLL-Progress Report.  Lead investigator:  Renier J. Brentjens
• Differential Gene Expression in CLL Cells. Lead investigator:  Shantaram S. Joshi, Ph.D., University of Nebraska Medical Center. 
• Global Methylation Profile of CLL Patients and its Implication in Therapy.  Lead Investigator:  Wei-Gang Tong, M.D., Ph.D., University of Texas M.D. Anderson Cancer Center.  The grant to Dr. Tong was made possible by the bequest of Dwight R. Hubert. 
• Global Methylation Profile of CLL Patients and its Implication in Therapy. Progress Report.  Lead Investigator:  Wei-Gang Tong
• Development of a Pharmacological Activator of STAT 1 for the Targeted Therapy of Chronic Lymphocytic Leukemia.  Lead investigator:  David A. Frank, M.D., Ph.D.,Dana Farber Cancer Institute.  The grant to Dr. Frank was made possible by the bequest of Dwight R. Hubert. 
• Analysis of Data from Phase II Study of Genesense (BCL-2 antisense) in Patients with Advanced Chronic Lympocytic Leukemia."  Investigators:  Drs. Susan O'Brien, Michael Keating, Michael Andreeff, and other physicians from the University of Texas M.D. Anderson Cancer Center. 
  
  PATIENT EDUCATION:
  
• Sponsored and participated in the making of the HealthTalk video:
  Participating in a Clinical Trial:  A Patient's Story.
  The story of Andrew Shorr's treatment in the Rituxan, Fludarabine and Cytoxan trial at MD Anderson Cancer Center.
  
• Sponsored the HealthTalk recording of the:
  CLL Patient Conference at Johns Hopkins Oncology Center on March 24, 2001
  Discussion on new therapies and developments for CLL,  an overview of the drug approval process and new developments at the FDA,  effective communication with your doctor from the physician's perspective and also recent immunologic approaches to CLL